bioMérieux
A global leader in in vitro diagnostics for clinical and industrial applications.
BIM | PA
Overview
Corporate Details
- ISIN(s):
- FR0013280286 (+13 more)
- LEI:
- 549300AK8Y0LBIQ4T071
- Country:
- France
- Address:
- 376 CHE DE L'ORME, 69280 MARCY-L'ETOILE
- Website:
- https://www.biomerieux.com/
- Sector:
- Manufacturing
Description
bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2022-08-31 19:04 |
Rapport Financier Semestriel 2022
|
French | PDF • 5.2 MB | ||
| 2022-08-31 07:01 |
bioMérieux – First-Half 2022 Results
|
English | PDF • 365.8 KB | ||
| 2022-08-31 07:01 |
bioMérieux – Résultats semestriels au 30 juin 2022
|
French | PDF • 370.2 KB | ||
| 2022-08-22 07:02 |
The SPECIFIC REVEAL® Rapid AST System has received Breakthrough Device Designat…
|
English | PDF • 210.3 KB | ||
| 2022-08-22 07:02 |
La Food and Drug Administration américaine accorde le statut de « Breakthrough …
|
French | PDF • 257.1 KB | ||
| 2022-08-02 14:13 |
Juillet 2022 – Déclaration sur le nombre d’actions composant le capital social …
|
French | PDF • 105.9 KB | ||
| 2022-07-28 07:05 |
bioMérieux receives FDA Clearance for NEPHROCHECK® test on VIDAS®
|
English | PDF • 224.5 KB | ||
| 2022-07-28 07:05 |
bioMérieux reçoit l’accréditation de la FDA pour le test NEPHROCHECK® sur VIDAS®
|
French | PDF • 258.7 KB | ||
| 2022-07-07 07:01 |
bioMérieux launches 3P® ENTERPRISE, an innovative solution to address the daily…
|
English | PDF • 234.4 KB | ||
| 2022-07-07 07:01 |
bioMérieux lance 3P® ENTERPRISE, une solution innovante pour relever les défis …
|
French | PDF • 233.9 KB | ||
| 2022-07-06 07:30 |
bioMérieux, Boehringer Ingelheim and Evotec launch Aurobac, a joint venture to …
|
English | PDF • 321.4 KB | ||
| 2022-07-06 07:30 |
bioMérieux, Boehringer Ingelheim et Evotec lancent la coentreprise Aurobac afin…
|
French | PDF • 323.3 KB | ||
| 2022-07-04 09:48 |
Juin 2022 - Déclaration sur le nombre d'actions composant le capital social et …
|
French | PDF • 105.9 KB | ||
| 2022-06-03 08:50 |
Mai 2022 - Déclaration sur le nombre d'actions composant le capital social et l…
|
French | PDF • 105.9 KB | ||
| 2022-05-23 16:40 |
AG 2022 - Descriptif du programme de rachat d'actions
|
French | PDF • 229.8 KB |
Automate Your Workflow. Get a real-time feed of all bioMérieux filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for bioMérieux
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for bioMérieux via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-09-04 | N/A | Other | Sell | 1,432 | 137,517.82 EUR |
| 2023-09-04 | N/A | Other | Sell | 1,253 | 120,328.10 EUR |
| 2023-09-01 | N/A | Other | Other | 2,900 | N/A |
| 2023-06-23 | N/A | Other | Other | 323 | 24,971.13 EUR |
| 2023-06-23 | N/A | Other | Buy | 323 | 24,971.13 EUR |
| 2023-06-23 | N/A | Other | Buy | 300 | 23,193.00 EUR |
| 2023-06-23 | N/A | Other | Buy | 25 | 1,932.75 EUR |
| 2023-03-23 | N/A | Other | Sell | 16,500 | 1,650,415.80 EUR |
Peer Companies
